With nanomolar affinity for BCL-2, BCL-XL and BCL-W [60], ABT-737 demonstrated single-agent efficacy against lymphoma and small-cell lung cancer (SCLC), and synergy in combination with chemotherapy and radiation in vitro and in vivo. This evidence concerns the gene BCL2L1 and small cell lung carcinoma.